Rachel Klemovitch, Assistant Editor05.17.24
Osteotec has partnered with SI-BONE to exclusively distribute the iFuse Implant System in the UK and Ireland. The iFuse Implant System is designed to provide sacroiliac (SI) joint stabilization and allow long-term fusion.
"We are pleased to be expanding our product offering to include the iFuse Implant System, and to be working with the UK's top spine surgeons to give them more options, expand our treatment offering and deliver better patient outcomes," Dean Stockwell, Osteotec Sales & Marketing Director, told the press. “We look forward to working with the SI-BONE team to increase and support sales through our expertise, ensuring our customers enjoy the best possible experience, service, and support in the industry."
The iFuse Implant System has been used in over 55,000 minimally invasive surgical SI joint infusions. The system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction which is a result of sacroiliac joint disruption and degenerative sacroiliitis.
"We are excited about working with Osteotec to expand our footprint in the UK and Ireland," said Neville Lorimer, SI-BONE Vice President, International. "With the assistance of Osteotec's talented commercial team and extensive industry knowledge, we will be able to accelerate our strategic objective of providing superior patient outcomes in these markets."
"We are pleased to be expanding our product offering to include the iFuse Implant System, and to be working with the UK's top spine surgeons to give them more options, expand our treatment offering and deliver better patient outcomes," Dean Stockwell, Osteotec Sales & Marketing Director, told the press. “We look forward to working with the SI-BONE team to increase and support sales through our expertise, ensuring our customers enjoy the best possible experience, service, and support in the industry."
The iFuse Implant System has been used in over 55,000 minimally invasive surgical SI joint infusions. The system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction which is a result of sacroiliac joint disruption and degenerative sacroiliitis.
"We are excited about working with Osteotec to expand our footprint in the UK and Ireland," said Neville Lorimer, SI-BONE Vice President, International. "With the assistance of Osteotec's talented commercial team and extensive industry knowledge, we will be able to accelerate our strategic objective of providing superior patient outcomes in these markets."